Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.
暂无分享，去创建一个
[1] Andrew B. Conley,et al. Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States , 2021, mBio.
[2] R. Wunderink,et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. , 2020, The Lancet. Infectious diseases.
[3] E. Burd,et al. Carbapenem-Resistant Klebsiella pneumoniae Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection , 2018, mBio.
[4] M. Hackel,et al. In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016 , 2017, Antimicrobial Agents and Chemotherapy.
[5] T. Read,et al. Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae , 2016, Nature Microbiology.